Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

Search results for

  • The legacy of the terrorist leader in Pakistan is mixed. Overall, support for his al-Qaida movement is down, according to opinion polls, but he remains a revered figure among militants. And the U.S. raid that killed him is still a source of friction between the U.S. and Pakistan.
  • Two men claim the al-Qaida leader traveled in a large convoy to a tribal area on the border with Afghanistan. He reportedly attended a dinner with some local elders. That conflicts with reports he was in hiding the last five years of his life.
  • Pharmaceutical company Pfizer has agreed to settle a lawsuit brought by Brigham Young University over the creation of the prescription pain reliever Celebrex. A jury trial had been scheduled to start later this month.
  • NATO would likely contribute some of the forces, but the U.S. would supply the bulk. They would include trainers as well as thousands of Green Berets and other special operations troops who would work with Afghans on counter-terror missions.
  • Linebacker Jonathan Vilma got the stiffest penalty. He will miss the entire 2012 season. The other suspensions range from three to eight games.
  • Babies are born too soon at a higher rate in the United States than in 125 other countries. The first worldwide rankings of preterm births show the problem isn't limited to the developing world.
  • Drum major Robert Champion died in November 2010. Authorities say it was a case of death by hazing.
  • Drinking has long been a part of life for many members of Parliament. But a fight started by one lawmaker has lead to new rules. Bartenders and other staff will be trained on how to cut off intoxicated politicians.
  • Mitt Romney, the presumed GOP presidential candidate, continues to try out potential running mates, though most deny any interest in the job. Sen. Marco Rubio, Rep. Paul Ryan, Sen. Rob Portman, Gov. Chris Christie and others have all made high-profile comments in recent days.
  • Years after more than 40 patients with HIV received immune cells designed to attack and kill cells infected with HIV, the specialized cells are still present in their bloodstreams. There's been no sign the cells, a form of gene therapy, caused any serious side effects.
1,411 of 29,989